489 related articles for article (PubMed ID: 29364548)
1. Efficacy of micafungin for the treatment of invasive candidiasis and candidaemia in patients with neutropenia.
Chandrasekar P; Sirohi B; Seibel NL; Hsu JW; Azie N; Wu C; Ruhnke M
Mycoses; 2018 May; 61(5):331-336. PubMed ID: 29364548
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of micafungin in invasive candidiasis caused by common Candida species with special emphasis on non-albicans Candida species.
Cornely OA; Vazquez J; De Waele J; Betts R; Rotstein C; Nucci M; Pappas PG; Ullmann AJ
Mycoses; 2014 Feb; 57(2):79-89. PubMed ID: 23786573
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of micafungin for treatment of serious Candida infections in patients with or without malignant disease.
Cornely OA; Marty FM; Stucker F; Pappas PG; Ullmann AJ
Mycoses; 2011 Nov; 54(6):e838-47. PubMed ID: 21668522
[TBL] [Abstract][Full Text] [Related]
4. Intermittent Dosing of Micafungin Is Effective for Treatment of Experimental Disseminated Candidiasis in Persistently Neutropenic Rabbits.
Petraitiene R; Petraitis V; Hope WW; Walsh TJ
Clin Infect Dis; 2015 Dec; 61 Suppl 6(Suppl 6):S643-51. PubMed ID: 26567283
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of micafungin monotherapy for candidemia and deep-seated candidiasis in adults with cancer.
Farmakiotis D; Tarrand JJ; Kontoyiannis DP
Antimicrob Agents Chemother; 2014 Jun; 58(6):3526-9. PubMed ID: 24637687
[TBL] [Abstract][Full Text] [Related]
6. Outcomes with micafungin in patients with candidaemia or invasive candidiasis due to Candida glabrata and Candida krusei.
Shorr AF; Wu C; Kothari S
J Antimicrob Chemother; 2011 Feb; 66(2):375-80. PubMed ID: 21147825
[TBL] [Abstract][Full Text] [Related]
7. Epidemiology of candidemia and antifungal susceptibility in invasive Candida species in the Asia-Pacific region.
Wang H; Xu YC; Hsueh PR
Future Microbiol; 2016 Oct; 11():1461-1477. PubMed ID: 27750452
[TBL] [Abstract][Full Text] [Related]
8. Outcomes by
Locke JB; Pillar CM; Castanheira M; Carvalhaes CG; Andes D; Aram JA; Andrzejewski C; Bartizal K; Das AF; Sandison T; Thompson GR; Pappas PG
Antimicrob Agents Chemother; 2024 May; 68(5):e0158423. PubMed ID: 38526046
[TBL] [Abstract][Full Text] [Related]
9. Micafungin: a review of its use in adults for the treatment of invasive and oesophageal candidiasis, and as prophylaxis against Candida infections.
Cross SA; Scott LJ
Drugs; 2008; 68(15):2225-55. PubMed ID: 18840009
[TBL] [Abstract][Full Text] [Related]
10. Pharmacoeconomic analysis of antifungal therapy for primary treatment of invasive candidiasis caused by Candida albicans and non-albicans Candida species.
Ou HT; Lee TY; Chen YC; Charbonneau C
BMC Infect Dis; 2017 Jul; 17(1):481. PubMed ID: 28693479
[TBL] [Abstract][Full Text] [Related]
11. Economic evaluation of micafungin vs. liposomal amphotericin B (LAmB) for the treatment of candidaemia and invasive candidiasis (IC).
Neoh CF; Liew D; Slavin MA; Marriott D; Chen SC; Morrissey O; Stewart K; Kong DC
Mycoses; 2013 Sep; 56(5):532-42. PubMed ID: 23496163
[TBL] [Abstract][Full Text] [Related]
12. Economic evaluation of micafungin versus caspofungin for the treatment of candidaemia and invasive candidiasis.
Neoh CF; Liew D; Slavin MA; Marriott D; Chen SC; Morrissey O; Stewart K; Kong DC
Intern Med J; 2013 Jun; 43(6):668-77. PubMed ID: 23461421
[TBL] [Abstract][Full Text] [Related]
13. Micafungin use in children.
Emiroglu M
Expert Rev Anti Infect Ther; 2011 Sep; 9(9):821-34. PubMed ID: 21905789
[TBL] [Abstract][Full Text] [Related]
14. Pharmacoeconomic evaluation of micafungin versus caspofungin as definitive therapy for candidaemia and invasive candidiasis (IC) in Turkey.
Neoh CF; Senol E; Kara A; Dinleyici EC; Turner SJ; Kong DCM
Eur J Clin Microbiol Infect Dis; 2018 Mar; 37(3):537-544. PubMed ID: 29185089
[TBL] [Abstract][Full Text] [Related]
15. [Scientific evidence supporting the use of micafungin in the treatment of invasive candidiasis].
Montejo M; Quindós G
Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 2():15-22. PubMed ID: 21420572
[TBL] [Abstract][Full Text] [Related]
16. [Micafungin in invasive candidiasis among oncohematological patients].
Jarque I; Angel Sanz M
Rev Iberoam Micol; 2009 Mar; 26(1):75-7. PubMed ID: 19463282
[TBL] [Abstract][Full Text] [Related]
17. Development of New Strategies for Echinocandins: Progress in Translational Research.
Walsh TJ; Azie N; Andes DR
Clin Infect Dis; 2015 Dec; 61 Suppl 6():S601-3. PubMed ID: 26567276
[TBL] [Abstract][Full Text] [Related]
18. Micafungin: a review of its use in the prophylaxis and treatment of invasive Candida infections in pediatric patients.
Carter NJ; Keating GM
Paediatr Drugs; 2009; 11(4):271-91. PubMed ID: 19566111
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of micafungin versus caspofungin for treatment of systemic Candida infections in the UK.
Sidhu MK; van Engen AK; Kleintjens J; Schoeman O; Palazzo M
Curr Med Res Opin; 2009 Aug; 25(8):2049-59. PubMed ID: 19575628
[TBL] [Abstract][Full Text] [Related]
20. Economic evaluation of micafungin versus liposomal amphotericin B (LAmB) for treating patients with candidaemia and invasive candidiasis (IC) in Turkey.
Neoh CF; Senol E; Kara A; Dinleyici EC; Turner SJ; Kong DCM
Eur J Clin Microbiol Infect Dis; 2018 Sep; 37(9):1777-1784. PubMed ID: 29959610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]